Collegium Pharmaceutical, Inc. (COLL) Scheduled to Post Quarterly Earnings on Wednesday
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is scheduled to announce its earnings results before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. On average, analysts expect Collegium Pharmaceutical to post $-3 EPS for the current fiscal year and $-1.92 EPS for the next fiscal year.
Shares of Collegium Pharmaceutical, Inc. (NASDAQ COLL) opened at 10.33 on Wednesday. The company’s 50 day moving average is $10.82 and its 200 day moving average is $10.81. Collegium Pharmaceutical, Inc. has a one year low of $9.01 and a one year high of $18.02. The company’s market cap is $305.42 million.
TRADEMARK VIOLATION NOTICE: “Collegium Pharmaceutical, Inc. (COLL) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/01/collegium-pharmaceutical-inc-coll-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Several equities analysts have recently weighed in on COLL shares. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. HC Wainwright started coverage on shares of Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 target price for the company. BidaskClub downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, September 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $20.00.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.